An AI platform for creating bacteriophage treatments for infections.
A universal, scale-independent artificial intelligence-based platform for manufacturing high titer bacteriophage preparations for clinical applications
This study is working on a smart technology that helps create special viruses called bacteriophages, which can help fight off tough bacterial infections, especially those that don't respond to regular antibiotics, making it easier for patients to get the treatment they need.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Intralytix, INC. NIH-funded |
| Lab location | 1 site (Columbia, UNITED STATES) |
| Project ID | NIH-10671440 on NIH RePORTER |
What this research studies
This research focuses on developing an advanced artificial intelligence platform that can efficiently produce high concentrations of bacteriophages, which are viruses that specifically target and kill bacteria. By utilizing AI, the platform aims to streamline the manufacturing process, making it more scalable and adaptable for clinical applications. Patients with bacterial infections, particularly those caused by antibiotic-resistant Gram-negative bacteria, may benefit from these tailored bacteriophage preparations. The approach combines cutting-edge technology with innovative treatment strategies to address the growing issue of antibiotic resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by Gram-negative bacteria that are resistant to conventional antibiotics.
Not a fit: Patients with infections caused by bacteria that are not Gram-negative or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for patients suffering from antibiotic-resistant bacterial infections.
How similar studies have performed: Other research has shown promise in using bacteriophages as a treatment for bacterial infections, indicating that this approach has potential for success.
Where this research is happening
Columbia, UNITED STATES
- Intralytix, INC. — Columbia, United States (Active)
Researchers
- Principal investigator: Ruzicka, Mel — Intralytix, INC.
- Study coordinator: Ruzicka, Mel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.